Evercore is the cleanest pure-play on the reawakening M&A and advisory cycle. The franchise has now posted four consecutive, escalating earnings beats — culminating in a record Q1'26 adjusted EPS of $7.53 (vs $5.43 consensus) as adjusted advisory fees jumped 123% year over year Investing.com· Q1'26. At ~20x earnings on inflecting numbers, with a balance sheet that returns capital rather than dilutes it, this is a high-quality cyclical breakout setup — not a value trap.
Evercore is the largest independent investment-banking advisory firm in the world by revenue and consistently ranks as the #3 global advisory franchise behind only Goldman Sachs and Morgan Stanley. Unlike the bulge brackets, Evercore takes no balance-sheet risk and runs no large trading book — it sells advice: M&A, restructuring, capital advisory, and shareholder engagement, plus a smaller Investment Management arm.
Two segments drive the model. Investment Banking & Equities — the engine — is where advisory fees, underwriting, and the Evercore ISI equities platform live. Investment Management contributes wealth and institutional asset management. Crucially, roughly 45% of net revenue is now non-M&A (restructuring, capital advisory, equities, underwriting), which diversifies the franchise across the cycle. Evercore reported a record $3.88B in FY25 net revenue, and the TTM figure has already climbed to ~$4.55B as the deal cycle reaccelerates StockAnalysis· TTM. A record class of newly hired Senior Managing Directors (SMDs) is the firm's forward pipeline: rainmakers take 12–24 months to ramp, so 2026 hiring seeds 2027 fees.
Evercore is an advisory investment bank, so the right lens is net revenue, the compensation ratio, advisory fees, operating margin and capital return — not gross margin or EBITDA. The key tell here is operating leverage: revenue is growing faster than comp, so margins are expanding.
| Metric | Value | Signal |
|---|---|---|
| Net Revenue (TTM) | $4.55B | Record · +18% vs FY25 |
| Net Revenue (FY25) | $3.88B | Record year |
| Adj. Advisory Fees (Q1'26) | ~$1.2B | +123% YoY |
| Adj. Compensation Ratio | 64% | -170 bps YoY |
| Adj. Operating Margin (Q1'26) | 25.3% | +870 bps YoY |
| Net Income (TTM) | $809.6M | Inflecting |
| Adj. EPS Diluted (TTM) | $17.75 | vs $14.56 FY25 (adj.) |
| P/E (TTM) | 20.1x | Reasonable on growth |
| Fwd P/E | 19.8x | Cycle-justified |
| Capital Returned (9M'25) | $623.8M | Net buyback |
| Analyst Target (mean) | $374.60 | Buy consensus |
The valuation deserves a clear-eyed look. P/E ~20 is above Evercore's mid-cycle average for a reason — earnings are inflecting hard off a deal-cycle trough. On forward numbers the multiple is ~19.8x, and if the advisory upcycle persists, FY26 consensus EPS leaves the stock in the mid-teens forward. This is not a nosebleed multiple (no MPWR-style ~60x here); it is a quality cyclical paying ~20x at the start of an upswing, which keeps the valuation axis intact for an A+ grade.
| Last Price | $357.38 |
| RSI (14) | 58.4 |
| EMA 20 | $344.49 |
| EMA 50 | $337.08 |
| EMA 200 | $321.33 |
| ATR (14) | $12.78 |
| Extension vs EMA20 | +3.7% |
Textbook bullish structure. The EMA stack is perfectly ordered — EMA20 ($344.49) > EMA50 ($337.08) > EMA200 ($321.33) — with price riding above all three. RSI at 58.4 sits in the healthy momentum band, well short of overbought, leaving room before any mean-reversion. Price is only ~3.7% extended above the EMA20, so this is not a chase. ATR of $12.78 (~3.6%) frames clean risk: a pullback into the $344–$350 EMA20 zone is the high-probability entry, with the EMA50 around $337 acting as the trend floor. The stock sits ~8% below its 52-week high of $388.71 — enough headroom for a measured-move push toward prior highs Yahoo Finance· live.
For a recommendation to clear our bar, the cap table has to be clean — no active ATM, no toxic financing, no recent equity raise, no reverse split. Evercore passes decisively. A pull of the SEC EDGAR filing history (CIK 1360901) shows only routine forms — 8-K earnings releases, 10-Q/10-K, proxy DEF 14A, and insider Form 4s. There is a standing automatic shelf (S-3ASR, last refiled Nov 2023) — boilerplate for any WKSI of this size — but no 424B equity offering has been drawn since 2015, there is no at-the-market program, no PIPE, no convertibles and no warrants. The only equity-plan filing is a routine S-8 (employee comp). The shelf is dormant; the firm is a net repurchaser, not an issuer.
A high-quality franchise with a pristine balance sheet — but the highest-beta name in this cohort (1.49). The dominant risk is not company-specific; it is the cyclicality of the deal market itself. Advisory fees are the first line item to retreat if the M&A cycle stalls or the tape turns risk-off.
The company-specific risks here are genuinely low — no dilution, no leverage stress, improving margins, a Buy consensus. What keeps the gauge at a moderate 5/10 is pure cyclicality: with a 1.49 beta, EVR is the cohort's highest-octane name, and its core revenue line is the most macro-sensitive. In a continuing risk-on, deal-friendly tape this is exactly the franchise you want; in a sharp risk-off, it draws down faster than its peers. Trade it as a high-conviction cyclical, not a defensive compounder.
Buy the highest-quality pure-play on the M&A reawakening into a controlled pullback. The math: from a $350.00 limit entry, the $332.00 stop risks $18.00 while TP1 at $380.00 offers $30.00 — a clean 1.67R to the first target, and 3.06R if the breakout extends to $405.00. The $350 entry sits right on the EMA20 pullback zone, so you are buying the trend at support rather than chasing it. The stop tucks just under the EMA50 ($337) — a daily close below it would mark a genuine break of the uptrend, not just noise.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, StockAnalysis, MarketBeat, and SEC EDGAR. Accuracy is not guaranteed.